Refractory Indolent B-Cell Non-Hodgkin Lymphoma

DBCOND0165948Hematologic Neoplasms

Refractory Indolent B-Cell Non-Hodgkin Lymphoma is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as
refractory indolent B cell non-hodgkin lymphoma
Classified under
Indicated drugs

What you can answer from here — as of November 14, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not prose
Sign in
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which approved drugs for Refractory Indolent B-Cell Non-Hodgkin Lymphoma share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In